Alnylam Pharmaceuticals | ALNY - Operating Expenses


Alnylam Pharmaceuticals reported $965.32M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amgen USD 5.9B 773M Dec/2025
Arrowhead Research USD 223.22M 10.86M Dec/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
Moderna USD 1.54B 259M Dec/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Novartis USD 9.77B 401M Sep/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 10.71B 1.32B Dec/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Takeda JPY 1.02T 400.98B Dec/2025
Tectonic Therapeutic USD 21.89M 440K Sep/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025
Xencor USD 68.52M 8.26M Sep/2025